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Abstract: The synthesis of some novel 3’-spirocyclic-oxindole compounds, based on the 
spiro[indole-3,5`-isoxazolidin]-2(1H)-one, the 2`H-spiro[indole-3,6`-[1,3]oxazinane]-2,2`(1H)-
dione and the 2`H-spiro[indoline-3,3`-pyrrolo[1,2-c][1,3`]oxazine]-1`,2(1H)-dione heterocyclic 
structures, are described.  These compounds were prepared from methyl -(2-nitrophenyl)acrylate 
via [1,3]-dipolar cycloaddition reactions with two acyclic nitrones and one cyclic nitrone followed 
by reduction of the cycloadducts and then treatment with triphosgene.  Two of these compounds 
showed significant cytostatic activity on three cancer cell lines with GI50 values of 2.6-4.1 M on 
the human breast cancer cell line, MCF-7.  
 
Key words: isoxazolidine, oxazinane, oxindole, nitrones, [1,3]-dipolar cycloaddition, 
spirocyclic compounds, cytotoxic activity. 
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1. Introduction 
3’-Spirocyclo-oxindoles, of synthetic or natural origin, have a range of biological activities.1  As 
part of a medicinal chemistry project we have been focusing on the synthesis of novel 3’-
spirocyclo-oxindoles as scaffolds for new drug discovery.2,3  As an extension of this project we 
required the synthesis of the novel 3’-spirocyclic-oxindoles of the type B and D. These were 
planned to be accessed from the isoxazoline intermediate A which in principle could be formed via 
a [1,3]-dipolar cycloaddition reaction between the acrylate 12-4 and nitrones.  Regioselective 
reduction of A would provide isoxazolidine spirocyclic oxindoles B, while further reduction would 
provide the amino-alcohol C which upon treatment with phosgene, or its equivalent, was expected 
to provide oxazinane spirocyclic oxindoles of the type D (Scheme 1).  
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During the course of this project Parmar et al.1f reported the synthesis of isoxazolidine spirocyclic 
oxindoles, related to B, from the [1,3]-dipolar cycloaddition of the 3-methyleneindolone derivative 
2a (R = CO2Et) with nitrones (Figure 1), while Williams,
5 Wang1a and Schreiber6 have earlier 
3 
described [1,3]-dipolar cycloadditions of azomethine ylides to 2a (R = CO2Et, aryl and CO2allyl) 
and their 5- and 6-substituted derivatives to provide novel spirocyclic structures.  Some of these 
were found to be a new class of non-peptide, small molecule MDM2-p53 inhibitors, a relatively 
new target for cancer chemotherapy.1a In 1998, Melot7 reported the synthesis of isoxazolidine 
spirocyclic isoindolines, compounds isomeric to B, using a nitrone cycloaddition reaction of 3-
methyleneisoindolines 2b. 
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We report here our efforts for preparing novel spirocycles related to B and D and their 
stereochemistries and the cytostatic activities of some of these compounds against three cancer-cell 
lines.  
 
2. Results and Discussion 
Initial investigations on the [1,3]-dipolar cycloaddition of 1 with nitrones involved a study of the 
reaction of 1 and the nitrone 3a. Heating a dichloromethane solution of 1 and 3a (1.1 molar equiv.) 
at 60o C in a sealed tube for 4 d resulted in a mixture of 1, 4a and 5a, from which pure samples of 
4a and 5a could be isolated in yields of 26% and 20%, respectively after purification by column 
chromatography (Scheme 2).  Heating a mixture of 1 and 3a (1.1-1.2 molar equiv.) at 150o C in a 
microwave reactor in toluene solution, or in the absence of solvent, for 30 min resulted in the 
isolation of pure samples of 1, 4a and 5a, in yields of 29%, 15% and 30%, respectively.  In each 
case unreacted dipolarophile (1) was isolated. When pure cycloadduct 4a was heated at 150o C in a 
microwave reactor without solvent for 30 min, a 42 : 30 : 28 mixture of 1, 4a and 5a, respectively, 
was produced. This experiment clearly demonstrated the reversible nature of the cycloaddition 
reaction between 1 and 3a and also helped to explain the lack of complete consumption of the 
4 
dipolarophile in these reactions. We assume that the nitrone 3a was also generated in this 
experiment but it could not be detected from 1H NMR analysis of the crude reaction mixture.  We 
suspect that 3a was unstable to the thermal conditions.  Heating a mixture of 1 and nitrone 3b (1.3 
molar equiv.) at 150o C in a microwave reactor in the absence of solvent resulted in ca 20 : 60 : 20 
mixture of 1, 4b and 5b, respectively from 1H NMR analysis.  Separation of this mixture by column 
chromatography gave pure samples of 1, 4b and 5b, in yields of 11%, 58%, and 6%, respectively 
and a mixture of 1 and 5b that was difficult to separate. 
Scheme 2 (compounds 4 and 5 are racemic) 
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1H NMR analysis clearly indicated that 4a,b and 5a,b were all 5-isoxazolidinecarboxylate 
regioisomers (with the expected three proton coupled spin system of H-3 and H4 and H-4 clearly 
evident) and not the alternative 4-isoxazolidinecarboxylate regioisomers.  The structure of 4a was 
unequivocally determined by a single crystal X-ray structural determination (Figure 2)8 which 
indicated that 4a was the 5-exo isomer and thus indicated that 5a was the 5-endo isomer.  
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Figure 2. Molecular projection of 4a (50% probability displacement amplitude ellipsoids for non-
hydrogen atoms, hydrogen atoms having arbitrary radii of 0.1 Å/  O(1)-N(2) is 1.472(3) Å. 
 
 
Heating a toluene solution of a mixture of 1 and the cyclic nitrone 6 at 150o C for 30 min in a 
microwave reactor gave a ca 33 : 50 : 17 mixture of 1, 7 and 8, respectively (from 1H NMR 
analysis).  Separation of this mixture by column chromatography gave pure samples of 7 and 8, in 
yields of 40%, and 6%, respectively and a mixture of 1 and 8 that was difficult to separate.  
1H NMR analysis clearly indicated that 7 and 8 were both pyrrolo[1,2-b]isoxazole-2-carboxylate 
regioisomers (with the expected three proton coupled spin system of H-3a and H-3 and H-3 
clearly evident). The relative stereochemistry of these adducts was assigned based on NOESY 
studies.  These studies showed cross-peaks between HO and the most upfield H-3 proton (H-3) for 
both compounds 7 and 8 while cross-peaks were observed between H-3a and H-3 in 7 and 
between H-3a and H-3 (in C6D6) in 8.  This analysis indicated that 7 was the endo-isomer and 8 
the exo-isomer.   
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Scheme 3 (compounds 7 and 8 are racemic)   
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Treatment of 4a over 10% Pd/C under a hydrogen atmosphere gave a mixture of the isoxazolidine 
spirocyclic oxindole 9a and its further reduced product 10a from which 9a could be isolated in pure 
form in 24% yield (Scheme 4). The formation of the oxindole ring in 9a was clearly evident from 
13C NMR analysis with a resonance at  179.4 for the oxindole carbonyl group. Treatment of 4b 
under similar conditions gave 10b in 55% yield.  Treatment of 4a or 4b with activated zinc dust in 
glacial acetic acid under sonication conditions for 1 h provided 10a and 10b, in respective yields of 
58% and 90% (Scheme 4).  Treatment of these compounds with triphosgene under basic conditions 
(Et3N) gave the oxazinane spirocyclic oxindoles 11a and 11b in respective yields of 61% and 68% 
(Scheme 4). The 13C NMR spectra of these compounds clearly showed resonances for the oxindole 
(ca  170) and oxazinanone (ca  150) carbonyl groups. 
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Scheme 4 (compounds 9-11 are racemic)a 
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a Reagents and conditions: (a) 10% Pd/C, H2 (1 atm), EtOAc, rt, 18h; 9a (24%), 10b (55%). (b) Zn 
dust (10 equiv), HOAc, sonication, rt, 1 h; 10a (58%), 10b (90%). (c) triphosgene, Et3N, THF, rt; 
11a (61%, 3 days), 11b (68%, 2 days). 
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The compounds 12-16 were prepared in a similar fashion according to Schemes 5 and 6. All 
attempts at the hydrogenation of 7 or 8 over 10% Pd/C or the reduction of these compounds with 
zinc dust in glacial acetic acid under sonication conditions gave rise to complex reaction mixtures. 
However, hydrogenation/hydrogenolysis of 8 over PdCl2 in methanol followed by treatment of the 
crude reaction mixture with triphosgene/Et3N gave the desired tetracyclic spiro compound 16 in 
25% overall yield (Scheme 6). 
 
Scheme 5 (compounds 12-14 are racemic)a 
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a Reagents and conditions: (a) 10% Pd/C, H2 (1 atm), EtOAc, rt, 18h; 54%. (b) Zn dust (10 equiv), 
HOAc, sonication, rt, 1 h, 94%. (c) triphosgene, Et3N, THF, rt, 2 days, 51%. 
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Scheme 6 (compounds 15 and 16 are racemic)a 
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a Reagents and conditions: (a) PdCl2, H2 (1 atm), MeOH, rt, 3h. (b) triphosgene, Et3N, THF, rt, 2 
days, 25% overall from 8. 
 
3. Cytostaticity Studies 
Cytostaticity studies against the cancer cell lines, H460 (human non small cell lung), MCF-7 
(human breast) and SF-268 (human CNS) were performed at the Peter MacCallum Cancer Institute, 
Melbourne, Australia, using standard NCI protocols.  Initially the percentage cell growth of cells 
incubated with 25 M of compounds 4a, 7, 9, 10b, 11a, 11b and 14 was measured after 72 h.  The 
results are presented in Table 1. 
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Table 1. Cytostatic studies on cancer cell lines. 
Entry Compound Percentage Cell Growth 
H460 MCF-7 SF-268 
1 4a 64 97 78 
2 7 2 7 (GI50 = 4.1  0.2 M) 18 
3 9 0 1 (GI50 = 2.6  0.1 M) 14 
4 10b 55 107 78 
5 11a 63 79 77 
6 11b 58 85 79 
7 14 80 101 100 
 
The initial screening indicated that only compounds 7 and 9 had an appreciable cytostatic activity 
against all three cell lines at 25 M (Table 1, entries 2 and 3).  The GI50 (concentration for 50% of 
growth inhibition) on these compounds on MCF-7 cells was 4.1 and 2.6 M, respectively as 
extrapolated from duplicate studies of growth inhibition over a drug concentration of 0-25 M (see 
Supporting Information). It was observed that 9 had a much sharper GI curve (see Figures A and B 
in Supporting Information) than 7 (see Figures C and D in Supporting Information), which may 
suggest that it has a narrow therapeutic index, that is there is a fineline between no activity and high 
toxicity. Furthermore at higher doses of 9, cytotoxicity as opposed to cytostaticity was clearly 
demonstrated as fewer cells remained at the end of the assay than when at the beginning. 
Interestingly, while the isoxazolidine spirocyclic isoindoline 9 had the most cytostatic activity, its 
ring expanded analogues, 11a,b having an oxazinane ring rather than a isoxazolidine showed little 
activity.  This may be a function of the differences in ring size (5 versus 6) and/or the basicity of the 
respective nitrogen atoms.  
In conclusion, the synthesis of some novel 3’-spirocyclic-oxindole compounds, based on the 
spiro[indole-3,5`-isoxazolidin]-2(1H)-one, the 2`H-spiro[indole-3,6`-[1,3]oxazinane]-2,2`(1H)-
dione and the 2`H-spiro[indoline-3,3`-pyrrolo[1,2-c][1,3`]oxazine]-1`,2(1H)-dione heterocyclic 
structures has been achieved.   These compounds were prepared from methyl -(2-
nitrophenyl)acrylate 1 via [1,3]-dipolar cycloaddition reactions with two acyclic nitrones and one 
cyclic nitrone followed by reduction of the cycloadducts and then treatment with triphosgene.  Two 
11 
of these compounds showed significant cytostatic activity on three cancer cell lines with GI50 values 
of 2.6-4.1 M on the human breast cancer cell line, MCF-7.   
  
Experimental 
Petrol refers to the fraction of petroleum spirit with a boiling point of 40-60 C.  All 1H NMR 
spectra were performed at 300 MHz and all 13C NMR (DEPT) spectra at 75 MHz in CDCl3 
solution, unless otherwise noted. All spectra were referenced to CDCl3 (
1H  7.26 ppm and 13C 
NMR  77.00 ppm). 1H NMR assignments were achieved with the aid of gCOSY, and in some 
cases NOESY and TOCSY experiments. 13C NMR assignments were based upon DEPT, gHSQC 
and gHMBC experiments. All solvents were dried over anhydrous magnesium sulfate, unless stated 
otherwise. The atom numbering for compounds 4a and 7 and 9 and their derivatives is as indicated 
below. 
 
 
 
 
 
 
 
 
 
 
 
 
Methyl (3`R*, 5`R*)-2`-methyl-5`-(2-nitrophenyl)-3`-phenylisoxazolidine-5`-carboxylate (4a) 
and Methyl (3`S*, 5`R*)-2`-methyl-5`-(2-nitrophenyl)-3`-phenylisoxazolidine-5`-carboxylate 
(5a) 
The title compounds were prepared using two methods. Method 1: To a solution of 1 (110 mg, 5.3 
 10-4 mol) in anhydrous CH2Cl2 (1 mL), contained within a sealed tube was added nitrone 3a (85.5 
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mg, 6.3  10-4 mol). The tube was sealed and the mixture was left stirring at 60 C for 4 d. 1H NMR 
analysis of the crude reaction mixture revealed the ratio of 4a : 5a : 1 was 59 : 33 : 8. The mixture 
was purified by column chromatography using 30% EtOAc:petrol as eluent to yield 4a as a yellow 
oil (47.2 mg, 1.3  10-4 mol, 26%, Rf = 0.37 in EtOAc/petrol (1 : 9)) and 5a as a yellow oil (36.8 
mg, 1.1  10-4 mol, 20%, Rf = 0.16 in EtOAc/petrol (1 : 9)) and a mixture of 1 and 5a. Method 2: A 
mixture of 1 (581.4 mg, 2.8 mmol) and nitrone 3a (379 mg, 2.8 mmol) was placed in a sealed glass 
microwave reaction vessel. The mixture was subjected to microwave-assisted heating at 150 C for 
30 min (CEM microwave reactor with temperature and pressure control). 1H NMR analysis of the 
crude reaction mixture revealed the ratio of 4a : 5a : 1 was 27 : 39 : 34. The mixture was purified by 
column chromatography using CH2Cl2/petrol/MeOH (1 : 4 : 0.1) as eluent to yield 4a as off-white 
clear crystals (149.7 mg, 4.4 10-4 mol, 15%, m.p. 124-126 °C) and a mixture of 5a and 1. The 
mixture was further purified by column chromatography using 20% EtOAc:petrol as eluent to yield 
5a as a yellow oil (285 mg, 8.3  10-4 mol, 30%) and recovered 1 (168 mg, 8.0  10-4 mol, 29%).  
4a: MS (EI) m/z 342 (19%) [M.+], 296 (9%), 220 (11%), 134 (88%); 118 (5%), 104 (89%); HRMS 
(EI) Calcd for C18H18N2O5 [M
.+] 342.1216. Found: 342.1217. 1H NMR (500 MHz)  8.22 (d, J 7.5 
Hz, 1H, ArCH-6); 8.14 (d, J 7.5 Hz, 1H, ArCH-3); 7.74 (t, J 7.5 Hz, 1H, ArCH-5 ); 7.53 (t, J 7.5 
Hz, 1H, ArCH-4); 7.49 (d, J 7.3 Hz, 2H, ArCH-o); 7.36 (t, J 7.3 Hz, 2H, ArCH-m); 7.32 (t, J 7.3 
Hz, 1H, ArCH-p); 3.88 (bt, J 11.7 Hz, 1H, CHCH-4`); 3.75 (s, 3H, CO2CH3); 3.54 (bs, 1H, CH-
3`); 2.73 (s, 3H, NCH3); 2.62 (dd, J 13.5, 7.0 Hz, 1H, CHCH-4`). 
13C NMR (125 MHz)  169.6 
(CO2); 146.3 (ArC-2); 137.3 (ArC-1); 136.9 (ArC-i); 133.8 (ArCH-5); 128.75 (ArCH-4); 128.72 
(ArCH-m); 128.4 (ArCH-o); 128.2 (ArCH-p); 127.7 (ArCH-6); 125.3 (ArCH-3); 82.8 (C-5`); 73.4 
(CH-3`); 53.0 (CO2CH3); 49.9 (CH2-4`); 43.0 (NCH3).  
5a: MS (EI) m/z 342 (13%) [M.+], 296 (4%), 220 (9%), 134 (89%); 118 (28%), 104 (72%); HRMS 
(EI) Calcd for C18H18N2O5 [M
.+] 342.1216. Found: 342.1220. 1H NMR (500 MHz)  8.29 (dd, J 
8.0, 1.5 Hz, 1H, ArCH-6); 8.14 (dd, J 8.0, 1.5 Hz, 1H, ArCH-3); 7.77 (dt, J 8.0, 1.5 Hz, 1H, ArCH-
5); 7.51 (dt, J 8.0, 1.5 Hz, 1H, ArCH-4); 7.30-7.23 (m, 5H, ArCH-o, ArCH-m and ArCH-p); 3.97 (t, 
J 9.0, 7.5 Hz, 1H, CH-3`); 3.92 (dd, J 12.7, 6.5 Hz, 1H, CHCH-4`); 3.73 (s, 3H, CO2CH3); 2.72 
(s, 3H, NCH3); 2.39 (dd, J 13.0, 9.5 Hz, 1H, CHCH-4`). 
13C NMR (125 MHz)  169.0 (CO2); 
146.3 (ArC-2); 139.2 (ArC-1); 137.1 (ArC-i); 134.3 (ArCH-5); 128.7 (ArCH-o); 128.5 (ArCH); 
128.3 (ArCH); 128.2 (ArCH); 127.7 (ArCH-m); 125.2 (ArCH-3); 85.5 (C-5`); 74.1 (CH-3`); 53.0 
(CO2CH3); 51.8 (CH2-4`); 43.0 (NCH3).  
 
Methyl (3`R*, 5`R*)-5`-(2-nitrophenyl)-2`,3`-diphenylisoxazolidine-5`-carboxylate (4b) and 
Methyl (3`S*, 5`R*)-5`-(2-nitrophenyl)-2`,3`-diphenylisoxazolidine-5`-carboxylate (5b) 
13 
A mixture of 1 (133.7 mg, 6.5  10-4 mol) and nitrone 3b (164.7 mg, 8.4  10-4 mol) was placed in a 
sealed glass microwave reaction vessel. The mixture was subjected to microwave-assisted heating 
at 150 C for 30 min. 1H NMR analysis of the crude reaction mixture revealed the ratio of 4b : 5b : 
1 was 62 : 21 : 17. The mixture was purified by column chromatography using 0-10% EtOAc in 
petrol as eluent to yield 4b as a bright yellow oil (151.3 mg, 3.7 10-4 mol, 58%, Rf = 0.72 in  
EtOAc/petrol (1 : 9)) and a mixture of 5b and 1. The mixture was further purified using a 
chromatotron® (0-2.5% EtOAc in petrol) to yield 5b as a yellow oil (14.9 mg, 3.7  10-5 mol, 6%, 
Rf = 0.31 in EtOAc/petrol (1 : 9)) and recovered 1 (15.3 mg, 7.4  10-5 mol, 11%) and a mixture of 
5b and 1 (43.6 mg).  
4b: MS (EI) m/z 404 (58%) [M.+], 345 (2%) [M+-CO2Me], 296 (7%), 220 (17%), 194 (21%), 180 
(32%), 134 (26%), 104 (91%); HRMS (EI) Calcd for C23H20N2O5 [M
.+] 404.1372. Found: 
404.1357. 1H NMR (500 MHz)  8.37 (dd, J 8.3, 1.3 Hz, 1H, ArCH-6); 8.14 (dd, J 8.3, 1.3 Hz, 1H, 
ArCH-3); 7.76 (dt, J 8.3, 1.3 Hz, 1H, ArCH-5); 7.52 (dt, 8.3, 1.3 Hz, 1H, ArCH-4); 7.31 (d, J 7.3 
Hz, 2H, ArCH-o); 7.27 (t, J 7.3 Hz, 2H, ArCH-m); 7.24 (t, J 7.3 Hz, 1H, ArCH-p); 7.21 (t, J 8.0 Hz, 
2H, ArCH-m`); 7.05 (d, J 8.0 Hz, 2H, ArCH-o`); 7.01 (t, J 8.0 Hz, 1H, ArCH-p`); 4.83 (dd, J 9.5, 
7.5 Hz, 1H, CH-3`); 4.12 (dd, J 13.5, 7.5 Hz, 1H, CHCH-4`); 3.67 (s, 3H, CH3); 2.54 (dd, J 13.5, 
9.5 Hz, 1H, CHCH-4`). 
13C NMR (125 MHz)  168.6 (CO2Me); 149.3 (ArC-i`); 146.5 (ArC-2); 
139.3 (ArC-i); 137.9 (ArC-1); 134.3 (ArCH-5); 128.6 (ArCH-m`); 128.84 (ArCH-m`); 128.82 
(ArCH-4); 128.1 (ArCH-6); 127.9 (ArCH-p); 127.0 (ArCH-o); 125.2 (ArCH-3); 123.8 (ArCH-p`); 
117.7 (ArCH-o`); 85.6 (C-5`); 71.0 (CH-3`); 52.9 (CH3); 51.9 (CH2-4`). 
5b: MS (EI) m/z 404 (52%) [M.+], 345 (2%) [M+-CO2Me], 296 (10%), 220 (18%), 194 (22%), 180 
(39%), 134 (26%), 104 (92%). HRMS (EI) Calcd for C23H20N2O5 [M
.+] 404.1372. Found: 
404.1358. 1H NMR  8.15 (dd, J 8.1, 1.2 Hz, 1H, ArCH-3); 8.12 (dd, J 7.8, 1.2 Hz, 1H, ArCH-6); 
7.68 (dt, J 7.8, 1.2 Hz, 1H, ArCH-5); 7.53 (dt, J 8.1, 1.2 Hz, 1H, ArCH-4); 7.51 (d, J 6.9 Hz, 2H, 
ArCH-o); 7.36 (t, J 6.9 Hz, 2H, ArCH-m); 7.32 (t, J 6.9 Hz, 1H, ArCH-p); 7.20 (t, J 6.9 Hz, 2H, 
ArCH-m`); 7.02 (d, J 6.9 Hz, 2H, ArCH-o`); 7.02-6.98 (m, 1H, ArCH-p`); 4.37 (dd, J 9.3, 7.5 Hz, 
1H, CH-3`); 3.93 (dd, J 13.5, 9.3 Hz, 1H, CHCH-4`); 3.78 (s, 3H, CH3); 2.89 (dd, J 13.5, 7.5 Hz, 
1H, CHCH-4`). 
13C NMR (125 MHz)  169.1 (CO2Me); 148.5 (ArC-i`); 146.5 (ArC-2); 138.8 
(ArC-i); 136.9 (ArC-1); 133.8 (ArCH-5); 128.95 (ArCH-4); 128.89 (ArCH-m); 128.5 (ArCH-m`); 
128.0 (ArCH-p); 128.1 (ArCH-6); 127.6 (ArCH-o); 125.4 (ArCH-3); 123.5 (ArCH-p`); 118.0 
(ArCH-o`); 84.2 (C-5`); 69.0 (CH-3`); 53.1 (CH3); 50.9 (CH2-4`). 
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Methyl (2`R*, 3a`S*)-2`-(2-nitrophenyl)hexahydropyrrolo[1,2-b]isoxazole-2`-carboxylate (7) 
and Methyl (2`R*, 3a`R*)-2`-(2-nitrophenyl)hexahydropyrrolo[1,2-b]isoxazole-2`-carboxylate 
(8) 
To 1 (87.7 mg, 4.2  10-4 mol) in a sealed glass microwave reaction vessel was added a solution of 
nitrone 6 (72 mg, 8.5  10-4 mol) in anhydrous toluene (0.4 mL). The mixture was subjected to 
microwave-assisted heating at 150 C for 30 min. 1H NMR analysis of the crude reaction mixture 
revealed the ratio of 7 : 8 : 1 was 49 : 18 : 33. The crude mixture was purified by column 
chromatography using 20-100% EtOAc:petrol as eluent to yield 7 as a light-yellow crystalline solid 
(51.2 mg, 1.7  10-4 mol, 40%, Rf = 0.54 in EtOAc/petrol (3 : 7)) and 8 as a light yellow 
semicrystalline oil (7.3 mg, 2.5  10-5 mol, 6%, Rf = 0.22 in EtOAc/petrol (3 : 7)) and recovered 1 
(35.6 mg, 1.7  10-4 mol, 40%).  
7: MS (EI) m/z 292 (33%) [M.+], 257 (34%), 244 (52%), 233 (85%), 104 (96%); HRMS (EI) Calcd 
for C14H16N2O5 [M
.+], 292.1059. Found: 292.1051. 1H NMR  8.20 (dd, J 8.1, 1.5 Hz, 1H, ArCH-
6); 8.13 (dd, J 8.1, 1.5 Hz, ArCH-3); 7.71 (dt, J 7.2, 1.5 Hz, 1H, ArCH-5); 7.47 (dt, J 7.2, 1.5 Hz, 
1H, ArCH-4); 3.66 (s, 3H, OCH3); 3.63-3.55 (m, 2H, CHACHB-6` and CH-3a`); 3.50 (dd, J 13.2, 
3.6 Hz, 1H, CHCH-3`); 3.05 (dt, J 13.5, 8.1 Hz, 1H, CHBCHA-6`); 2.58 (dd, J 13.2, 8.1 Hz, 1H, 
CHCH-3`); 2.21-2.01 (m, 2H, CHACHB-4` and CHACHB-5`); 1.99-1.89 (m, 1H, CHBCHA-4`); 
1.84-1.74 (m, 1H, CHBCHA-5`). 
13C NMR  168.9 (CO2); 146.1 (ArC-2); 139.2 (ArC-1); 134.2 
(ArCH-5); 128.5 (ArCH-4); 128.4 (ArCH-6); 125.3 (ArCH-3); 87.5 (C-2`); 66.7 (CH-3a`); 56.8 
(CH2-6`); 53.0 (OCH3); 47.9 (CH2-3`); 29.9 (CH2-4`); 23.7 (CH2-5`). 
13C NMR (C6D6) 169.1 
(CO2); 147.0 (ArC-2); 140.1 (ArC-1); 133.7 (ArCH-5); 129.4 (ArCH-6); 128.0 (ArCH-4); 125.1 
(ArCH-3); 87.9 (C-2`); 67.0 (CH-3a`); 57.0 (CH2-6`); 52.5 (OCH3); 48.5 (CH2-3`); 30.2 (CH2-4`); 
24.1 (CH2-5`).  
8: MS (EI) m/z 292 (12%) [M.+], 257 (18%), 244 (25%), 233 (39%), 104 (49%); HRMS (ESI+ve) 
Calcd for C14H17N2O5 [MH
+] 293.1132. Found: 293.1130. 1H NMR (500 MHz)  8.06 (dd, J 8.0, 
1.3 Hz, 1H, ArCH-3); 8.01 (dd, J 8.0, 1.3 Hz, 1H, ArCH-6), 7.67 (dt, J 8.0, 1.3 Hz, 1H, ArCH-5); 
7.50 (dt, J 8.0, 1.3 Hz, 1H, ArCH-4); 4.02-3.96 (m, 1H, CH-3a`); 3.82 (dd, J 13.0, 8.0 Hz, 1H, 
CHCH-3`); 3.71 (s, 3H, OCH3); 3.54 (ddd, J 13.8, 8.0, 4.0 Hz, 1H, CHACHB-6`); 3.11 (dt, J 13.8, 
8.0 Hz, 1H, CHBCHA-6`); 2.07 (dd, J 13.0, 4.0 Hz, 1H, CHCH-3`); 2.11-2.02 (m, 1H, CHACHB-
5`); 1.94 (dt, J 13.0, 8.0 Hz, 1H, CHACHB-4`); 1.84-1.76 (m, 1H, CHBCHA-5`); 1.46 (ddt, J 13.0, 
9.0, 4.0 Hz, 1H, CHBCHA-4`). 
13C NMR  169.7 (CO2); 146.6 (ArC-2); 136.9 (ArC-1); 133.8 
(ArCH-5); 128.7 (ArCH-4); 126.9 (ArCH-6); 125.1 (ArCH-3); 85.5 (C-2`); 66.9 (CH-3a`); 56.9 
(CH2-6`); 52.9 (OCH3); 46.0 (CH2-3`); 31.0 (CH2-4`); 24.1 (CH2-5`). 
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2`-Methyl-(3`S*, 5`R*)-3`-phenylspiro[indole-3,5`-isoxazolidin]-2(1H)-one (9) 
To a solution of 4a (54 mg, 1.6  10-4 mol) in EtOAc (1 mL) under an atmosphere of N2 was added 
10% Pd/C (9 mg). The vessel was then flushed with H2 and left stirring under an atmosphere of H2 
(balloon) for 18 h. The crude mixture was filtered through a bed of celite, washed with EtOAc (3  
50 mL) and the filtrate was evaporated in vacuo. The crude product was purified by column 
chromatography using 30-50% EtOAc in petrol as eluent to yield 9 as a yellow oil (10.6 mg, 3.8  
10-5 mol, 24%, Rf = 0.18 in EtOAc/petrol (3 : 7)). MS (EI) m/z 280 (10%) [M
.+], 263 (15%), 145 
(37%) [M+-C6H5CHNCH3O], 134 (92%), 117 (42%); HRMS (EI) Calcd for C17H16N2O2 [M
.+] 
280.1212. Found: 280.1206. 1H NMR (500 MHz)  8.79 (bs, 1H, NH); 7.57 (d, J 7.0 Hz, 2H, 
ArCH-o); 7.44 (d, J 7.5 Hz, 1H, ArCH-4); 7.39 (t, J 7.5 Hz, 2H, ArCH-m); 7.34 (d, J 7.5 Hz, 1H, 
ArCH-p); 7.28 (t, J 7.5 Hz, 1H, ArCH-6); 7.10 (t, J 7.5 Hz, 1H, ArCH-5); 6.94 (d, J 7.5 Hz, 1H, 
ArCH-7); 3.85 (bs, 1H, CH-3`); 3.01 (t, J 13.0 Hz, 1H, CHCH-4`); 2.77 (dd, J 13.0, 6.5 Hz, 1H, 
CHCH-4`); 2.71 (s, 3H, NCH3). 
13C NMR (125 MHz)  179.4 (C-2); 141.1 (ArC-7a); 137.0 
(ArC-i); 130.5 (ArC-3a); 130.1 (ArCH-6); 128.8 (ArCH-m); 128.5 (ArCH-o); 128.4 (ArCH-p); 
124.3 (ArCH-4); 123.1 (ArCH-5); 110.5 (ArCH-7); 80.5 (C-3); 74.5 (CH-3`);  49.3 (CH2-4`); 43.7 
(NCH3). 
 
(2R*, 3R*)-3-Hydroxy-3-[2-(methylamino)-2-phenylethyl]-1,3-dihydro-2H-indol-2-one (10a)  
To a solution of 4a (78.4 mg, 2.3  10-4 mol) in glacial AcOH (9.2 mL) was added activated Zn 
dust (150 g, 2.3 mmol). The mixture was sonicated for 1 h. The crude mixture was then filtered 
through a bed of celite and washed with EtOAc. The filtrate was washed with sat. Na2CO3 solution 
and then H2O, then dried, filtered and evaporated in vacuo. The crude was purified by column 
chromatography using 10-30% EtOAc in petrol as eluent to yield 10a as a yellow oil (37.6 mg, 1.3 
 10-4 mol, 58%, Rf = 0.16 in EtOAc/petrol (3 : 7)). MS (EI) m/z 282 (12%) [M.+], 206 (6%), 146 
(13%), 134 (21%), 120 (91%), 104 (12%); HRMS (EI) Calcd for C17H18N2O2 [M
.+]  282.1368. 
Found: 282.1365. 1H NMR (500 MHz)  7.32 (t, J 7.3 Hz, 2H, ArCH-m); 7.30-7.26 (m, 1H, ArCH-
p); 7.15-7.11 (m, 3H, ArCH-4 and ArCH-o); 7.08 (t, J 7.5 Hz, 1H ArCH-6); 6.71 (t, J 7.3 Hz, 1H 
ArCH-5); 6.67 (d, J 7.5 Hz, 1H ArCH-7); 4.70 (dd, J 7.5, 6.0 Hz, 1H, CH); 2.98 (dd, J 14.0, 8.0 Hz, 
1H, CHACHB); 2.76 (s, 3H, NHCH3); 2.48 (dd, J 14.0, 6.0 Hz, 1H, CHBCHA). 
13C NMR (125 MHz) 
 175.7 (C-2); 145.4 (ArC-7a); 139.7 (ArC-i); 129.2 (ArCH-6); 128.9 (ArCH-m); 128.1 (ArCH–p); 
126.8 (ArCH-o); 126.7 (ArC-3a and ArCH-4); 118.6 (ArCH-5); 118.4(ArCH-7); 79.4 (C-3); 61.8 
(CH); 42.4 (CH2); 28.8 (NHCH3). 
 
(2R*, 3S*)-3-(2-Anilino-2-phenylethyl)-3-hydroxy-1,3-dihydro-2H-indol-2-one (10b)  
16 
The title compound was prepared using two methods. Method 1: The title compound was prepared 
from 4b (61 mg, 1.5  10-4 mol) using a similar method to that described for the preparation for 
10a. The crude product was purified by column chromatography using 20-40% EtOAc in petrol as 
eluent to yield 10b as a yellow oil (28.6 mg, 8.3  10-5 mol, 55%, Rf = 0.66 in 40% EtOAc/petrol (2 
: 3)). Method 2: The title compound was prepared from 4b (72.7 mg, 1.8  10-4 mol) using a 
similar method to that described for the preparation for 10a. After following the same workup 
procedure, the crude mixture was purified by column chromatography using 10-20% EtOAc in 
petrol as eluent to yield 10b as a cream solid (55.5 mg, 1.6  10-4 mol, 90%) and purified further by 
recrystallision to yield 10b as a cream solid (29.8 mg, 8.7  10-5 mol, 48%). MS (EI) m/z 344 (15%) 
[M.+], 148 (11%), 196 (46%), 120 (43%), 182 (92%), 104 (16%). HRMS (EI) Calcd for C22H20N2O2 
[M.+] 344.1525. Found: 344.1505. 1H NMR (500 MHz)  7.36 (d, J 8.5 Hz, 2H, ArCH-o`); 7.27-
7.21 (m, 6H, ArCH-m`, ArCH-o, and ArCH-m); 7.20-7.15 (m, 2H, ArCH-p and ArCH-6); 7.09 (t, J 
7.5 Hz, 1H, ArCH-p`) 6.94 (d, J 7.5 Hz, 1H, ArCH-4); 6.77 (d, J 7.5 Hz, 1H, ArCH-7); 6.71 (t, J 
7.5 Hz, 1H, ArCH-5); 4.97 (dd, J 9.7, 6.0 Hz, 1H, CH); 4.66 (bs, 1H, NH); 3.34 (dd, J 13.0, 6.0 
Hz, 1H, CHCH); 2.42 (dd, J 13.0, 9.7 Hz, 1H, CHCH). 
13C NMR (125 MHz)  175.3 (C-2); 
146.0 (ArC-7a); 139.1 (ArC-i); 136.8 (ArC-i`); 129.5 (ArCH-6); 128.8 (ArCH-m`); 128.7 (ArCH-
m); 128.0 (ArCH-p); 127.0 (ArCH-o); 125.9 (ArCH-4); 125.8 (ArCH-p`); 124.4 (ArC-3a); 123.4 
(ArCH-o`); 118.3(ArCH-5); 118.0(ArCH-7); 79.8 (C-3); 60.1 (CHPh); 43.5 (CH2). 
 
2`-Methyl-(3`R*, 5`R*)-3`-phenylspiro[indole-3,5`-isoxazolidin]-2(1H)-one (12) 
The title compound was prepared from 5a (78 mg, 2.3  10-4 mol) using a similar method to that 
described above for the preparation of 9. However, the reaction was left for only 2 h. The crude 
product was purified by column chromatography using 30-50% EtOAc in petrol to yield 12 as a 
yellow oil (34.8 mg, 1.2  10-4 mol, 54%, Rf = 0.16 in 30% EtOAc/petrol (3 : 7)). MS (EI) m/z 280 
(13%) [M.+], 263 (22%), 145 (58%), 134 (94%), 117 (63%); HRMS (ESI+ve) Calcd for 
C17H17N2O2 [MH
+] 281.1285. Found: 281.1293. 1H NMR (500 MHz)  8.05 (bs, 1H, NH); 7.53 (d, 
J 7.5 Hz, 1H, ArCH-4); 7.50 (d, J 7.5 Hz, 2H, ArCH-o); 7.38 (d, J 7.5 Hz, 2H, ArCH-m); 7.33 (t, J 
7.5Hz, 1H, ArCH-p); 7.25 (t, J 7.5 Hz, 1H, ArCH-6); 7.08 (t, J 7.5Hz, 1H, ArCH-5); 6.85 (d, J 7.5 
Hz, 1H, ArCH-7); 4.23 (bm, 1H, CH-3`); 3.01 (dd, J 13.0, 6.0 Hz, 1H, CHCH-4`); 2.79 (s, 3H, 
NCH3); 2.74-2.70 (m, 1H, CHCH-4`). 
13C NMR  178.2 (C-2); 140.7 (ArC-7a); 137.7 (ArC-i); 
130.7 (ArC-3a); 129.7 (ArCH-6); 128.8 (ArCH-m); 128.1 (ArCH-p); 127.6 (ArCH-o); 124.7 
(ArCH-4); 123.3 (ArCH-5); 110.3 (ArCH-7); 81.8 (C-3); 72.9 (CH-3`); 49.7 (CH2-4`); 43.9 
(NCH3). 
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(2R*, 3S*)-3-hydroxy-3-[2-(methylamino)-2-phenylethyl]-1,3-dihydro-2H-indol-2-one (13)  
The title compound was prepared from 5a (49 mg, 1.43  10-4 mol) using a similar method to that 
described above for the synthesis of 10a. Compound 13 was obtained as a yellow oil, which 
required no further purification (38 mg, 1.35  10-4 mol, 94%, Rf = 0.45 in EtOAc/petrol (3 : 7)). 
MS (EI) m/z 282 (31%) [M.+], 146 (18%), 134 (26%), 120 (89%), 104 (13%); HRMS (EI) Calcd for 
C17H18N2O2 [M
.+], 282.1368. Found: 282.1366. 1H NMR  7.39-7.34 (m, 3H, ArCH-m and ArCH-
p); 7.26 (dd, J 7.0, 1.5 Hz, 2H, ArCH-o); 7.13 (dt, J 8.1, 1.5 Hz, 1H, ArCH-6); 6.89 (dd, J 8.1, 1.5 
Hz, 1H, ArCH-4); 6.71 (t, 7.0 Hz, 2H, ArCH-5 and ArCH-7); 4.27 (dd, J 9.0, 6.0 Hz, 1H, CH); 3.15 
(dd, J 13.2, 6.0 Hz, 1H, CHACHB); 2.71 (s, 3H, NHCH3); 2.34 (dd, J 13.2, 9.0 Hz, 1H, CHBCHA). 
13C NMR  176.1 (C-2); 146.0 (ArC-7a); 138.7 (ArC-i); 129.0 (ArCH-m); 128.5 (ArCH-p); 127.4 
(ArCH-o); 129.2 (ArCH-6); 125.7 (ArCH-4); 124.8 (ArC-3a); 118.0 (ArCH-5); 117.8 (ArCH-7); 
79.5 (C-3); 61.0 (CH); 43.5 (CH2); 28.3 (NHCH3).  
 
3`-Methyl-(4`R*, 6`R*)-4`-phenyl-2`H-spiro[indole-3,6`-[1,3]oxazinane]-2,2`(1H)-dione (11a)  
To a solution of 10a (68.2 mg, 2.4  10-4 mol) in anhydrous THF (2 mL) was added triphosgene 
(21.5 mg, 7.2  10-5 mol) and anhydrous NEt3 (0.07 mL, 4.8  10-4 mol). The mixture was stirred 
under N2 for 7 d. The reaction mixture was diluted with EtOAc and the solution was washed 
successively with H2O, sat. NaHCO3 solution and brine and then dried and evaporated under 
reduced pressure. The crude product was purified by column chromatography using 30-100% 
EtOAc:petrol to yield 11a as a white crystalline solid (45.9 mg, 1.5  10-4 mol, 61%, Rf = 0.25 in 
EtOAc/petrol ( 1 : 1), m.p. 200-204 C). MS (EI) m/z 308 (67%) [M.+], 309 (15%) [MH+], 251 
(91%) [M+-NMeCO], 206 (84%), 146 (94%) [M+-CH2C6H5CHNCH3CO], 130 (80%) [M
+-
CH2C6H5CHNCH3CO2], 118 (38%), 102 (43%); HRMS (EI) Calcd for C18H16N2O3 [M
.+] 308.1161. 
Found: 308.1161. 1H NMR (500 MHz)  9.02 (bs, 1H, NH); 7.45 (t, J 7.5 Hz, 2H, ArCH-m); 7.39 
(t, J 7.5 Hz, 1H, ArCH-p); 7.29-7.25 (m, 3H, ArCH-o and ArCH-6); 7.09-7.05 (m, 2H, ArCH-4 and 
ArCH-5); 6.89 (d, J 7.5 Hz, 1H, ArCH-7); 4.88 (dd, J 7.5, 7.0 Hz, 1H, CH-4`); 3.09 (dd, J 15.0, 
7.0 Hz, 1H, CHCH-5`); 2.76 (s, 3H, NCH3); 2.39 (dd, J 15.0, 7.0 Hz, 1H, CHCH-5`). 
13C NMR 
(125 MHz)  169.9 (C-2); 150.8 (C-2`); 138.8 (ArC-i); 135.6 (ArC-7a); 130.0 (ArCH-6); 129.3 
(ArCH-m); 128.7 (ArCH-p); 126.7 (ArCH-o); 124.4 (ArCH-4); 123.6 (ArCH-5); 118.4 (ArC-3a); 
115.0 (ArCH-7); 86.1 (C-3); 60.8 (CH-4`); 43.6 (CH2-5`); 29.0 (NCH3).  
 
3`-Phenyl-(4`R*, 6`R*)-4`-phenyl-2`H-spiro[indole-3,6`-[1,3]oxazinane]-2,2`(1H)-dione (11b)  
The title compound was prepared from 10b (20.9 mg, 6.1  10-5 mol) using a similar method to that 
described above for the synthesis of 11a. However, the reaction was left for only 2 d. The crude 
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product was then purified by column chromatography using 30-100% EtOAc in petrol as eluent to 
yield 11b as a white crystalline solid (15.4 mg, 4.2  10-5 mol, 68%, Rf = 0.73 in MeOH:CHCl3 (1 : 
9), m.p. 256-258 C). MS (EI) m/z 370 (21%) [M.+], 251 (65%) [M+-PhNCO], 206 (46%), 180 
(30%), 146 (89%), 130 (53%), 103 (32%); HRMS (EI) Calcd for C23H18N2O3 [M
.+] 370.1317. 
Found: 370.1319. 1H NMR (dDMSO, 500 MHz)  10.4 (s, 1H, NH); 7.50 (d, J 7.5 Hz, 1H, ArCH-
4); 7.43 (d, J 7.5 Hz, 2H, ArCH-o`); 7.39 (d, J 7.5 Hz, 2H, ArCH-o); 7.33 (t, J 7.5 Hz, 1H, ArCH-
6); 7.29 (t, J 7.5 Hz, 2H, ArCH-m); 7.26 (t, J 7.5 Hz, 2H, ArCH-m`); 7.20 (t, J 7.5 Hz, 1H, ArCH-
p); 7.09 (t, J 7.5 Hz, 1H, ArCH-5); 7.08 (t, J 7.5 Hz, 1H, ArCH-p`); 6.91 (d, J 7.5 Hz, 1H, ArCH-
7); 5.83 (dd, J 7.5, 7.0 Hz, 1H, CH-4`); 3.37-3.30 (m, 1H, CHCH-5`); 2.40 (dd, J 14.3, 7.5 Hz, 
1H, CHCH-5`). 
13C NMR (dDMSO, 125 MHz)  169.5 (C-2); 149.1 (C-2`); 140.2 (ArC-i); 136.6 
(ArC-i`); 135.9 (ArC-7a); 130.0 (ArCH-6); 128.8 (ArCH-m); 128.6 (ArCH-m`); 127.9 (ArCH-p); 
127.0 (ArCH-o); 125.9 (ArCH-p`); 123.8 (ArCH-4); 123.6 (ArCH-o`); 122.9 (ArCH-5); 119.7 
(ArC-3a); 114.4 (ArCH-7); 84.2 (C-3); 58.8 (CH-4`); 42.5 (CH2-5`).  
 
3`-Methyl-(4`S*, 6`R*)-4`-phenyl-2`H-spiro[indole-3,6`-[1,3]oxazinane]-2,2`(1H)-dione (14)  
The title compound was prepared from 13 (41.8 mg, 1.5  10-4 mol) using a similar method to that 
described above for the synthesis of 11a. However, the reaction was left for only 2 d. The crude 
product was purified by column chromatography using 30-100% EtOAc in petrol as eluent to yield 
14 as a white crystalline solid (23.5 mg, 7.6  10-5 mol, 51%, Rf = 0.39 in EtOAc/petrol (1 : 1), m.p. 
244-248 C). MS (EI) m/z 308 (43%) [M.+], 251 (72%), 206 (68%), 146 (94%), 130 (65%); HRMS 
(EI) Calcd for C18H16N2O3 [M
.+] 308.1161. Found: 308.1166. 1H NMR (500 MHz, (CD3)2CO)  
9.27 (bs, 1H, NH); 7.49-7.48 (m, 4H, ArCH-o and ArCH-m); 7.43-7.40 (m, 1H, ArCH-p); 7.35 (d, J 
7.5 Hz, 1H, ArCH-4); 7.32 (dt, J 7.5, 1.2 Hz, 1H, ArCH-6); 7.07 (dt, J 7.5, 1.2 Hz, 1H, ArCH-5); 
7.03 (d, J 7.5 Hz, 1H, ArCH-7); 4.96 (dd, J 7.5, 7.0 Hz, 1H, CH-4`); 3.27 (dd, J 15.0, 7.5 Hz, 1H, 
CHCH-5`); 2.64 (s, 3H, NCH3); 2.47 (dd, J 15.0, 7.5 Hz, 1H, CHCH-5`). 
13C NMR ((CD3)2CO) 
 171.0 (C-2); 150.2 (C-2`); 141.0 (ArC-i); 137.4 (ArC-7a); 130.6 (ArCH-6); 129.9 (ArCH-m), 
129.3 (ArCH-p); 128.1 (ArCH-o); 124.5 (ArCH-4); 123.6 (ArCH-5); 121.7 (ArC-3a); 115.1 
(ArCH-7); 85.0 (C-3); 61.4 (CH-4`); 43.9 (CH2-5`); 28.6 (NCH3).  
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(3R*, 3R*)-3-Hydroxy-3-(pyrrolidin-2-ylmethyl)indol-2-one (15) and (3R*, 4a`R*)-2`H-
spiro[indoline-3,3`-pyrrolo[1,2-c][1,3`]oxazine]-1`,2(1H)-dione (16)  
To a solution of 8 (41.3 mg, 1.4  10-4 mol) in anhydrous MeOH (2 mL) under an atmosphere of N2 
was added PdCl2 (5.2 mg, 2.8  10-5 mol) and the vessel flushed with H2 and left stirring for 3 h 
under a H2 atmosphere (balloon). The crude mixture was then filtered through a bed of celite and 
the solid was washed with MeOH (10 mL). The solvent was evaporated in vacuo. The crude 
product was purified by column chromatography using 50-100% EtOAc in petrol as eluent, to yield 
material (15) that was impossible to analyse by NMR due to the broadening of all peaks, perhaps 
due to traces of palladium. To a solution of this material (28 mg, 1.2  10-4 mol) in anhydrous THF 
(1 mL) was added triphosgene (10.7 mg, 3.6  10-5 mol) and anhydrous NEt3 (0.03 mL, 2.4  10-4 
mol). The mixture was stirred under N2 for 2 d. The crude was then washed with H2O and extracted 
with EtOAc. The organic extracts were then successively washed with sat. NaHCO3 solution and 
brine, dried and evaporated under reduced pressure. The crude product was purified by 
chromatotron® (0-4% MeOH in CHCl3) to yield 16 as a brown semicrystalline oil (9.2 mg, 3.6  
10-5 mol, 25% over 2 steps).  
15: MS (EI) m/z 232 (10%) [M.+], 214 (6%) [M+-H2O], 149 (22%), 120 (34%), 86 (37%), 70 (77%), 
43 (96%); HRMS (EI) Calcd for C13H16N2O2 [M
.+] 232.1212. Found: 232.1206.  
16: MS (EI) m/z 258 (70%) [M.+], 259 (19%) [MH+], 214 (32%), 186 (24%), 174 (94%), 146 
(94%), 133 (50%), 117 (35%), 104 (29%). HRMS (EI) Calcd for C14H14N2O3 [M
.+] 258.1004. 
Found: 258.0997. 1H NMR  7.34-7.29 (m, 2H, ArCH-6 and ArCH-4); 7.10 (dt, J 7.5, 1.0 Hz, 1H, 
ArCH-5); 6.91 (dd, J 7.5, 1.0 Hz, 1H, ArCH-7); 4.11-4.01 (m, 1H, CH-4a`); 3.63-3.52 (m, 1H, 
CHACHB-7`); 3.20-3.12 (m, 1H, CHBCHA-7`); 3.00 (dd, J 13.3, 6.0 Hz, 1H, CHCH-4`); 2.36 (dd, 
J 13.3, 6.0 Hz, 1H CHCH-4`); 2.26-2.09 (m, 3H, CHACHB-5` and CH2-6`); 1.53-1.47 (m, 1H, 
CHBCHA-5`). 
13C NMR  171.5 (C-2); 151.6 (C-1`); 136.6 (ArC-7a); 121.5 (ArC-3a); 90.6 (C-3`); 
131.2 (ArCH-6); 124.3 (ArCH-4); 124.7 (ArCH-5); 115.6 (ArCH-7); 59.5 (CH-4a`); 42.5 (CH2-
7`); 43.1 (CH2-4`); 33.5 (CH2-5`); 27.1 (CH2-6`). 
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Supporting Information 
 
Structure determinations 
 Full spheres of CCD area-detector diffractometer data were measured (Bruker AXS 
instrument, -scans; monochromatic Mo K radiation;  = 0.7107 Å) yielding Nt(otal) reflections, 
these merging to N unique after 'empirical'/multiscan 'absorption correction' (proprietary software) 
(Rint cited), No (I > 2(I)) considered 'observed'.  All reflections were used in the full matrix 
refinements on F2, refining anisotropic displacement parameters for the non-hydrogen atoms, 
hydrogen atoms being included according to a riding model.  Reflection weights were of the form 
(2(F2) + nw F
2)-1.  Neutral atom complex scattering factors were employed within the SHELXL 97 
and Xtal 3.7 program systems. 
 
4a.  C18H18N2O5, M = 342.3.  Monoclinic, space group P21, a = 11.141(2), b = 6.866(1), c = 
11.390(2) Å, β = 112.291(2)º, V = 806.2 Å
3.  Dc (Z = 2) = 1.410 g cm
–3.  μMo = 0.10 mm
–1; 
specimen: 0.65 x 0.10 x 0.10 mm; 'T'min/max = 0.84 ('empirical correction'.  Monochromatic K 
radiation,  = 0.71073 Å, 2max = 55; 7451 CCD reflections merged to 2170 independent, 1902 
with I > 2(I); R1 = 0.054, wR2 = 0.014; S = 1.06 (weights: (2(F2) + (0.1019P)2 +  0.0404 P)–1 (P 
= (Fo + 2Fc)/3)).  |max| = 0.50 e Å
–3.  T ca. 170 K.  CCDC 633506. 
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Figure. GI50 curves in duplicate for 9 ((A) and B)) and 7 ((C) and D)) against a MCF-7 cell line. 
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